Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 21 and 85 years old~* First heart attack within 1 to 10 days~Exclusion Criteria:~* Positive for HIV 1 and 2~* Previous heart attack~* Pacemaker or other device~* Pregnant or breastfeeding~* Allergic to cow or pig derived products~* Previous bone marrow transplant~* Involved in another clinical trial within the past 30 days~* Alcohol or recreational drug abuse within the past 6 months~* Hepatitis Positive~* Major surgical procedure or major trauma within the past 14 days~* Body weight greater than 300 pounds~* Autoimmune disease ( e.g. Lupus, Multiple Sclerosis)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Provacel: Cohort 1 (Type: ACTIVE_COMPARATOR): ex vivo cultured adult mesenchymal stem cells
- Provacel: Cohort 2 (Type: ACTIVE_COMPARATOR): ex vivo cultured adult mesenchymal stem cells
- Provacel: Cohort 3 (Type: ACTIVE_COMPARATOR): ex vivo cultured adult mesenchymal stem cells
- Provacel: Cohort 4 (Type: ACTIVE_COMPARATOR): ex vivo cultured adult mesenchymal stem cells
- Placebo (Type: PLACEBO_COMPARATOR): ex vivo cultured adult mesenchymal stem cells

Based on this trial design, predict the completion outcome and termination type (if applicable).